Earlier Thursday, Left's Citron Research called Express Scripts the "Philidor of the pharma industry." » Read More
Double-digit percentage increases of drugs have been common since 2011, and quadruple-digit prices have been seen for many cheaper medications. » Read More
Michael Babich, the former CEO of the Arizona-based drug maker, was among five individuals charged in an indictment filed. » Read More
Citron Research tweeted that Express Scripts is "Philidor of the pharma industry," referring to Philidor Rx Services' alleged misconduct.
Bristol-Meyers Squibb will pay millions to resolve allegations that it improperly promoted a schizophrenia treatment for unapproved uses.
Actimmune failed to demonstrate a statistically significant benefit over a placebo in patients.
Donald Trump says he's going to bring down prescription drug prices. And here's why that's totally possible, says Jake Novak.
President-elect Donald Trump made his promise, which echoes past criticisms on drug pricing, in an interview for Time magazine's Person of the Year issue.
CNBC's David Faber reports the latest on Abbott Laboratories going to court in Delaware to end its proposed acquisition of Alere.
Britain's competition watchdog has fined Pfizer a record 84.2 million pounds ($107 million) for its role in ramping up the cost of an epilepsy drug by as much as 2,600 percent.
Jeff Jonas, Sage Therapeutics CEO, discusses his company's new drug to treat postpartum depression and the current drug pricing environment.
The drug is for the treatment of moderate to severe menapause symptoms like hot flashes and night sweats.
TJ Parker, PillPack co-founder & CEO, talks about his company's plans to disrupt the pharmacy businesses.
CNBC's Martin Soong reports on the growth potential of the pharmaceutical industry in India, the largest generic drug producer in the world.
CEO David Schenkein explained that concerns for the molecule were specific to an "extremely high dose, a dose that we would never use in patients."
Incyte president & CEO Herve Hoppenot speaks to CNBC's Meg Tirrell about the growth of bone marrow drug Jakafi, drug pricing under Donald Trump and the company's drug pipeline.
CNBC's Meg Tirrell speaks with Celgene CEO Mark Alles at the American Society of Hematology about the company's immunotherapy partnerships and the upcoming Trump administration.
Looking to improve your overall well-being? These apps can help you keep tabs on your health while reducing stress.
The agency said Friday that it approved a new indication for a drug marketed by Eli Lilly and Boehringer Ingelheim.
Get the best of CNBC in your inbox